Breast Cancer
Data from M. Kaufmann et al provide new insights into breast cancer
Published in Cancer Weekly, February 12th, 2008
According to a study from Frankfurt, Germany, "GABG-IV B-93 is a prospective, randomised study comparing goserelin (n=384) with no further treatment (n=392) in hormone receptor (HR)-negative breast cancer patients (n=465) after 3 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for patients with 0 - 3 positive lymph nodes (LN) or 4 cycles epirubicin, cyclophosphamide (EC) followed by 3 cycles CMF for patients with 4 - 9 positive LN. After completion of the ZEBRA trial the study was amended to enrol also HR-positive patients with 1 - 9 + LN (n=311)."
"After a median follow-up of 4.7 years neither HR-negative nor HR-positive patients showed a benefit for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-02-12)
More Articles from Cancer Weekly
- Cancer
Lung Cancer, 3rd Edition Available Now - Cancer
Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear - Cancer
Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models - Cancer Vaccines
Findings in cancer vaccines reported from R.M. Wong and co-researchers - Cancer Vaccines
New cancer vaccines findings from Shimane University, Medical Department published - Cancer Vaccines
Reports summarize cancer vaccines study results from Charles University - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
